Skip to main content

GI/Liver

Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth
Dr. John Cush @RheumNow( View Tweet )
May 14, 2022
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9
Eric Topol @EricTopol( View Tweet )
May 11, 2022
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96

Dr. John Cush @RheumNow( View Tweet )

May 07, 2022
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
Study of PCP Dx irritable bowel dz; 459 randomised to 8 weeks of oral antispasmodics or diet (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). Better responses with diet (71% vs 61%; p=0.03). Better adherence w/ diet. https://t.co/gmn45yQmuB https://t.co/8SP5Vfx71z
Dr. John Cush @RheumNow( View Tweet )
Apr 29, 2022
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
Liver,hepatic,red

Arthritis Predicts Hepatic Fibrosis in Hemochromatosis

Apr 25, 2022

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 



A total of 112 patients with a liver biopsy confirmed

Read Article
ABP 654 is a Ustekinumab (anti-IL-12/23) biosimilar from Amgen - 563 pt, phase 3 trial shown to be equivalent to originator in mod- severe plaque psoriasis (no meaningful differences). ABP 654 is also being developed for Crohns & UC. https://t.co/vDNfMXCWcC

Dr. John Cush @RheumNow( View Tweet )

Apr 19, 2022
ICYMI: 520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/PxrabHROPy https://t.co/UAw51Hb5vU
Dr. John Cush @RheumNow( View Tweet )
Apr 09, 2022
Avacopan efficacy in renal failure in AAV. Appears to have benefit in renal disease that is more marked the more severe the disease is #Vasculitis22 https://t.co/3zsxjTLj62
Richard Conway @RichardPAConway( View Tweet )
Apr 05, 2022
211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm
Dr. John Cush @RheumNow( View Tweet )
Apr 05, 2022
ICYMI: Environmental Pollutants Ups Autoimmune Disease Risk An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, CTDs and inflammatory bowel diseases (IBD).https://t.co/oKdgSZ2jAF https://t.co/WI7aShKR97
Dr. John Cush @RheumNow( View Tweet )
Mar 28, 2022
colitis.jpg

Spondyloarthritis in Early Crohn's Disease

Mar 02, 2022

Analysis of a German Crohn's disease cohort finds that in patients with early Crohn’s disease (CD), spondyloarthritis was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD.

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Feb 25, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.




  1. Diagnostic delay in axial spondyloarthritis? Systematic review

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Feb 03, 2022

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Dr. John Cush @RheumNow( View Tweet )

Feb 02, 2022
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
liver.jpg

Methotrexate and hepatic fibrosis: we must be doing something right

Dec 02, 2021

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in rheumatology, and the consequent frequency of patient counselling about it, relatively little

Read Article
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr

Dr. John Cush @RheumNow( View Tweet )

Nov 21, 2021
#ACR21 Thieves! TM11. Belly pain in patient with RA nodules: ⭐️ A: rheumatoid nodulosis of pancreas and duodenum. Great case! @Rheumnow https://t.co/PuO4tka3FJ
Nov 09, 2021
#ACR21 #Abstr1492 Could gut microbiome contribute to Anti-Ro+/autoimmunity in #lupus? Analyses of 125 stool samples from mother of children with neonatal lupus and/or heart block revealed its potential role in genetic-environment interaction @RheumNow https://t.co/FnJtZJSCRj https://t.co/ttRdP9NIrG
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
Cush ACR learning computer online

Day 2 Report from ACR21

Nov 08, 2021

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
Loved this session on: Preclinical Rheumatoid Arthritis- Can we stop RA? As a patient advocate living with RA, my providers have always ran tests on my microbiome. The findings have correlated with my disease flares, and was a big trigger overall. #ACR21 @ACRheum Thank you! https://t.co/6hm6hr85JS
Effie Koliopoulos @RisingAboveRa( View Tweet )
Nov 08, 2021
Love-hate relationship with #methotrexate. Side effects are common ex nausea/GI in 1/3 and alopecia in women. ?if you ask do you get more AES. Tough to treat especially SEs are early. ?Coach pt to help w persistence abst1444# @RheumNow #ACR21 https://t.co/NDQDVz8lk2
Nov 08, 2021
×